Back to Awarded Treatment Trials


Awarded Trial: 10T-002

Grant ID

10T-002

Illness

Schizophrenia

Primary Drug/Intervention

N-acetyl cysteine

Primary Dosage

3000 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Breier

Sample Size

60

Duration of Study Period for Each Subject

6 months

Outcome Measurements

N/A

Results

No significant differences between NAC and placebo on any region of interest examined including cortical white matter volume, and thickness of temporal, frontal and parietal cortices. NAC, compared to placebo, significantly improved PANSS total symptoms, PANSS disorganization and CGI severity, but not positive and negative symptoms, functioning or cognition.

Publication

Breier A, Liffick E, Hummer TA, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. https://doi.org/10.1016/j.schres.2018.03.012

Link

N/A

PI Name

Alan Breier

Degree

MD

Center

Department of Psychiatry

Institution

Indiana University School of Medicine

Address

Psychiatry Building, 1111 W. 10th Street

City or Town

Indianapolis

State or Province

IN

Zip or Postal Code

46202

Country

U.S.A.

Email Address

abreier@iupui.edu